Bulk Rituximab Immunological Product from Canada
Rituximab is a chimeric monoclonal antibody targeting CD20 on B-cells, used in lymphoma and autoimmune disease therapy. Classified under HTS 3002.13.0090 as an unmixed immunological product obtained via biotechnological processes, supplied in bulk for formulation. It regulates immunological processes as defined in chapter notes.
Duty Rate — Canada → United States
100%
Rate breakdown
9903.04.60100%Except as provided in heading 9903.04.61, patented pharmaceutical articles as provided for in subdivisions (c) and (d) of U.S. note 40 to this subchapter
9903.05.860%Articles provided for in subdivision (b) of U.S. note 52 to this subchapter
9903.05.900%Articles of aluminum, of steel or of copper or derivative aluminum or steel articles; passenger vehicles (sedans, sport utility vehicles, crossover utility vehicles, minivans and cargo vans) and light trucks; parts of passenger vehicles (sedans, sport utility vehicles, crossover utility vehicles, minivans and cargo vans) and light trucks; medium- and heavy-duty vehicles; parts of medium- and heavy-duty vehicles; wood products; patented pharmaceutical articles; and semiconductor articles, as provided in subdivision (f) of U.S. note 52 to this subchapter
Import Tips
• Submit IND or BLA documentation from FDA to prove therapeutic intent and avoid diagnostic reagent classification
• Use validated shipping containers with temperature loggers; temperature excursions above 8°C often result in rejection
• Avoid common error of declaring as 'parts' under 3006; confirm it's not a finished medical appliance